Picoperine

Picoperine

SCHEMBL137805

c1ccc(N(CCN2CCCCC2)Cc2ccccn2)cc1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.44
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LIN28A Q9H9Z2 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ALDH1A1 P00352 3/20 0.43
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
CXCR4 P61073 1/20 0.40
SIGMAR1 Q99720 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
GPR55 Q9Y2T6 1/20 0.39
LTA4H P09960 1/20 0.39
PTGS2 P35354 1/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
KCNA5 P22460 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Picoperine SCHEMBL209959 0.99 HRH3 (0.43) HRH3MAPTSMN1; SMN2LIN28ATDP1
Picoperine SCHEMBL1651072 0.99 HRH3 (0.43) HRH3MAPTSMN1; SMN2LIN28ATDP1
Picoperine SCHEMBL9184091 0.99 HRH3 (0.43) HRH3MAPTSMN1; SMN2LIN28ATDP1
Histapyrrodine SCHEMBL1651354 0.79 SIGMAR1 (0.51) MAPTSMN1; SMN2ALDH1A1SIGMAR1LTA4H
Histapyrrodine SCHEMBL142300 0.78 SIGMAR1 (0.54) MAPTSMN1; SMN2ALDH1A1SIGMAR1LTA4H
SCHEMBL18157925 0.77 SMN1; SMN2 (0.59) MAPTSMN1; SMN2LIN28ATDP1ALDH1A1
SCHEMBL29777383 0.77 SMN1; SMN2 (0.59) MAPTSMN1; SMN2LIN28ATDP1ALDH1A1
Histapyrrodine SCHEMBL316865 0.77 SIGMAR1 (0.53) MAPTSMN1; SMN2ALDH1A1SIGMAR1LTA4H
SCHEMBL3939455 0.75 HRH3 (0.55) HRH3ALDH1A1SIGMAR1
SCHEMBL14058727 0.75 HRH3 (0.55) HRH3ALDH1A1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1780 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3887519-B1 METHODS OF DETERMINING PH AND CALCIUM OR CHLORIDE CONCENTRATION IN SAMPLES UNIV CHICAGO (US) 2025-11-05 EP claimed
US-20250333746-A1 RNA-NANOSTRUCTURED DOUBLE ROBOTS AND METHODS OF USE THEREOF UNIV ARIZONA STATE (US) 2025-10-30 US claimed
US-12436156-B2 Methods of determining pH and calcium or chloride concentration in samples THE UNIVERSITY OF CHICAGO (US) 2025-10-07 US claimed
CN-118191045-A Electrochemiluminescence detection method for malathion 江西师范大学 2024-06-14 CN claimed
CN-117929334-A Method for detecting alkaline phosphatase based on copper nanoclusters 遵义医科大学 2024-04-26 CN claimed
CN-117538309-A Electrochemiluminescence detection method for malathion 江西师范大学 2024-02-09 CN claimed
CN-111650260-B Electrochemical detection method for chicken infectious bronchitis virus NNA strain 南京农业大学 2024-02-02 CN claimed
CN-114113271-B Preparation method of photoelectrochemical organic transistor sensor for detecting pesticide malathion 杭州富鼎检测有限公司 2023-12-15 CN claimed
CN-116411113-A Transgenic component detection method based on CRISPR Cas enzyme gene editing technology 中国热带农业科学院三亚研究院 2023-07-11 CN claimed
CN-114675038-B Thermal fluorescence analysis and detection method and kit for protein content 陕西科技大学 2023-02-10 CN claimed
US-20020151525-A1 Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation COLLINS DOUGLAS A (US) 2002-10-17 US claimed
WO-2002055530-A2 TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION MAYO FOUNDATION (US) 2002-07-18 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
CN-1281048-A Reconstituted human t-PA molecule and its engineering bacterium strain to express it UNIV WUHAN (CN) 2001-01-24 CN claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0440009-B1 DEVICE AND METHOD FOR THE MODULATED COOLING OF A MOVING CYLINDRICAL OBJECT CENTRE DE RECHERCHES METALLURGIQUES CENTRUM VOOR RESEARCH IN DE METALLURGIE Association sans but lucratif (BE) 1993-09-29 EP claimed
EP-0245456-A4 AIDS VIRUS GENE EXPRESSION. US COMMERCE (US) 1989-01-24 EP claimed
EP-0245456-A1 AIDS VIRUS GENE EXPRESSION THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) 1987-11-19 EP claimed
WO-1987002989-A1 AIDS VIRUS GENE EXPRESSION UNITED STATES OF AMERICA, REPRESENTED BY THE UNITE (US) 1987-05-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151525-A1 Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation PCNA, MKI67, SLC19A1 HRH3 2620/4885MAPT 2973/4885SMN1; SMN2 1690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.